Research
Hormonal
The dual stimulation of the GIP and GLP1 receptor may provide benefits in treating type 2 diabetes and obesity.
Consider dual receptor agonists in treatment plans for better outcomes in diabetes and obesity.
StrongSupportsmedium confidence
the benefits of the double stimulation of the GIP and the GLP1 receptor.
Why this rating
The claim is supported by new data discussed in the abstract.
Source
A „másik” inkretin – a glükózdependens insulinotrop polipeptid terápiás újrafelfedezése
Gábor Winkler et al. · Orvosi Hetilap · 2023
reviewCited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →